Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
MCP110
Cat. No.:
OB0225LY-0042
Appearance:
Liquid
Purity:
≥97%
Identity:
Confirmed by NMR and LC-MS.
Size:
Product Overview
Description:
MCP110 0 is a compound that has been developed as a modulator of various intracellular signaling pathways, with specific interest in its mechanisms of action.
Synonym:
MCP-110; MCP 110; 521310-51-0; N-(4-(Benzyloxy)-3-methoxybenzyl)-5-phenyl-N-(2-(pyridin-2-yl)ethyl)pentanamide; N-[(3-Methoxy-4-phenylmethoxyphenyl)methyl]-5-phenyl-N-(2-pyridin-2-ylethyl)pentanamide
CAS No.:
521310-51-0
Compound CID:
10229237
Formula:
C33H36N2O3
Formula Weight:
508.65
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
MCP110 can be used to explore treatments for diseases associated with dysregulated cell signaling, such as cancer and metabolic disorders.
Library Information
Targets:
Raf; Ras
Receptors:
Raf-1
Pathways:
GPCR/G protein; MAPK
Plate Number:
AOCL-1
Plate Location:
e4
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
245 mg/mL; 481.67 mM
